Zhou et al. found that CXCR4 may be a key player in tamoxifen resistance in breast cancer, as resistance is reversed when CXCR4 is knocked down or upon treatment with plerixafor due to inhibition of the AKT phosphorylation pathway [190]. This evidence concerns the gene CXCR4 and breast cancer.